Mathew Thomas

TL;DR: The efficacy and safety of the fully human monoclonal antibody belimumab (BLyS-specific inhibitor) was assessed in patients with active systemic lupus erythematosus in a multicentre phase 3 study done in Latin America, Asia-Pacific, and eastern Europe.

TL;DR: This work aimed to review how zoonotic diseases result from natural pathogen ecology, and how other circumstances, such as animal production, extraction of natural resources, and antimicrobial application change the dynamics of disease exposure to human beings.

TL;DR: A group of respected global health practitioners reflecting on lessons learned from the Ebola outbreak describe some of the major threats to individual and collective human health, as well as the values and recommendations that should be considered to counteract such threats in the future.

TL;DR: Belimumab appears to promote normalization of serologic activity and reduce BLyS-dependent B cell subsets in serologically and clinically active SLE.

TL;DR: The conclusion that belimumab in combination with standard SLE therapy was generally well tolerated in a predominantly autoantibody-positive population with active SLE is supported.